News
Destiny Pharma Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research
Significant clinical and commercial opportunity of NTCD-M3 confirmed…
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line Data Expected in the Third Quarter of 2022
LONDON and…
Destiny Pharma Lancet Report
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Important…
Amber Implants Closes US$10 M Series A Financing
The Hague, Netherlands, 19 January 2022: Amber Implants, an…
Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US
Emcitate® (tiratricol) is the first potential treatment of…
Destiny Pharma Strategy/Company/Ops Update
Brighton, United Kingdom, 17 January 2022 – Destiny Pharma…
Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact
Over US$ 550 million raised by portfolio companies in 2021
…
BioInnovation Institute Awarded Grant to Launch a New Initiative Focused on Women’s Health
COPENHAGEN, Denmark, 11 January 2022 – BioInnovation Institute…
Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes
First company to develop an AI product to predict egg viability…
Novo Holdings – Grant of DKK 200 million will create better future prospects for young Syrian refugees in Jordan
Youth unemployment in Jordan is record high, and up to 50% of…
Versameb to Attend Biotech Showcase 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused…
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
ENHANCE-2 Screening Complete with Full Enrollment Expected in…
Genmab and Synaffix Enter into License Agreement for ADC Technology
Synaffix to provide access to proprietary antibody-drug conjugate…
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona…
Novo Holdings participates in EUR 110 million first closing of Sound Bioventures Fund I
Copenhagen, Denmark – Novo Holdings, a leading international…
Novo Holdings to acquire Ritedose
Novo Holdings A/S (“Novo Holdings”) today announced that…
AMSilk Partners with Mercedes-Benz to Present a Sustainable Bio-Based Product
The use of a biotechnology-based and certified-vegan…
EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)
OSLO/LONDON, 22 December 2021: Christmas came early at EXACT…
Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes
COPENHAGEN, DENMARK — Novo Holdings, a leading international…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
